What is the long-term trend for Avalo Therapeutics's interest income (expense), nonoperating?

Over 4 years (2021 to 2025), Avalo Therapeutics's interest income (expense), nonoperating has grown at a 16.1% compound annual growth rate (CAGR), from -$2.39M to $4.35M.

Avalo Therapeutics AVTX Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

AbbVieABBV

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,783%

Enterprise value$929.6M-1,342%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's interest income (expense), nonoperating?: Avalo Therapeutics (AVTX) reported interest income (expense), nonoperating of $803K in Q1 2026.
How has Avalo Therapeutics's interest income (expense), nonoperating changed year-over-year?: Avalo Therapeutics's interest income (expense), nonoperating decreased by 30.1% year-over-year, from $1.15M to $803K.
What is the long-term trend for Avalo Therapeutics's interest income (expense), nonoperating?: Over 4 years (2021 to 2025), Avalo Therapeutics's interest income (expense), nonoperating has grown at a 16.1% compound annual growth rate (CAGR), from -$2.39M to $4.35M.